In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil

Cornea

Volumn 26, Issue 2, 2007, Pages 194-198

  Oliveira, Adália Dias Dourado ^a   D'Azevedo, Pedro Alves ^a,b   Francisco, Waldemar ^c   Höfling Lima, Ana Luisa ^a,d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^d Faculdade de Ciências Médicas da Santa Casa de São Paulo ^*  (Brazil)

Author keywords

Endophthalmitis; Fluoroquinolone; Keratitis; Minimal inhibitory concentration; Susceptibility testing

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BRAZIL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONJUNCTIVITIS; DRUG ACTIVITY; DRUG SENSITIVITY; ENDOPHTHALMITIS; HAEMOPHILUS; IN VITRO STUDY; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIA; BRAZIL; CIPROFLOXACIN; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES;

EID: 33846469890     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000248379.78777.f6     Document Type: Article

References (26)

1. Ogawa GS, Hyndiuk RA. The fluoroquinolones: new antibiotics in ophthalmology. Int Ophthalmol Clin. 1993;33:59-68.
2. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.
3. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
4. Chalita MR, Hofling-Lima AL, Paranhos A Jr, et al. Shifting trends in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol. 2004;137:43-51.
5. Kowalski RP, Yates KA, Romanowski EG, et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987-1991.
6. Osato MS, Jensen HG, Trousdale MD, et al. The comparative in vitro activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates. Am J Ophthalmol. 1989;108:380-386.
7. Jensen HG, Felix C. In vitro antibiotic susceptibilities of ocular isolates in North and South America. In Vitro Antibiotic Testing Group. Cornea. 1998;17:79-87.
8. Egger SF, Ruckhofer J, Alzner E, et al. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res. 2001;33:117-120.
9. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106:1313-1318.
10. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis. 2002;2:530-538.
11. Marangon FB, Miller D, Muallem MS, et al. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004;137:453-458.
12. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 1997;24(Suppl 1):S67-S73.
13. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004;49(Suppl 2):S73-S78.
14. Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol. 2004;15: 316-320.
15. Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX(R)). Surv Ophthalmol. 2005; 50(6 Suppl):S7-S15.
16. Graves A, Henry M, O'Brien TP, et al. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea. 2001;20:301-305.
17. SAS Institute. SAS 9.1.3 Help and Documentation. Cary, NC: SAS Institute; 2000-2004.
18. Conover WJ. Practical Nonparametric Statistics. New York:Wiley; 1980.
19. Good P. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York: Springer; 1994.
20. Glenn AW. Common Statistical Methods for Clinical Research: With SAS Examples. 2nd ed. Cary, NC: SAS Institute Inc.; 2002.
21. Westfall PH, Tobias RD, Rom D, et al. Comparisons and Multiple Tests. Using the SAS System. Cary, NC: SAS Institute Inc.; 1999.
22. Blondeau JM, Zhao X, Hansen G, et al. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433-438.
23. Callegan MC, Ramirez R, Kane ST, et al. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003;20:246-252.
24. Morrissey I, Burnett R, Viljoen L, et al. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect. 2004;49: 109-114.
25. Mather R, Karenchak LM, Romanowski EG, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
26. Wagner RS, Abelson MB, Shapiro A, et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol. 2005;123:1282-1283.